<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881166</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-0470-02</org_study_id>
    <nct_id>NCT00881166</nct_id>
  </id_info>
  <brief_title>Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors</brief_title>
  <acronym>SGI-0470-02</acronym>
  <official_title>Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel,
      carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing
      regimen will be enrolled in each treatment arm.

      Primary objective: Determine the MTD.

      Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect
      pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with
      specific SOC treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>March 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, pharmacodynamic effects on biomarker modulation.</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience DLT</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Malignant Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral MP-470 + paclitaxel/carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral MP-470 + carboplatin/etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral MP-470 + topotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral MP-470 + docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral MP-470 + Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-470 + topotecan</intervention_name>
    <description>Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-470 + docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-470 + erlotinib</intervention_name>
    <description>150 mg PO once daily at least 1 hour before or 2 hours after eating</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-470 + paclitaxel/carboplatin</intervention_name>
    <description>Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mgâˆ™min/mL on Day 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-470 + carboplatin/etoposide</intervention_name>
    <description>Carboplatin IV infustion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100mg/m2 IV infustion over 2 hours on Days 1-3</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel,
             carboplatin/etoposide, topotecan, docetaxel, or erlotinib.

          2. Must be able to read, understand, and sign the IRB approved Informed Consent Form.

          3. At least 18 years old.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          5. Adequate bone marrow function; normal renal and hepatic function, normal cardiac
             function.

        Exclusion Criteria:

          1. Any other active invasive malignancy except non-melanoma skin cancers or cervical
             carcinoma in situ.

          2. History of significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure and/or myocardial infarction.

          3. Received any anticancer agent(s) within the past 3 weeks, including investigational
             agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic
             or hormonal therapy other than LHRH agonists.

          4. Received prior radiation therapy within the past 4 weeks.

          5. Any serious, uncontrolled active infection that requires systemic treatment or known
             infection with HIV, HCV or HBV.

          6. Patient requires treatment with immunosuppressive agents other than corticosteroids
             appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Tolcher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The START Center for Cancer Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Mita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Therapy and Research Center, Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premiere Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premiere Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Berk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astex Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie Murphy Veterans Memorial Hospital (VA)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC at the UT Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapy (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MP-470</keyword>
  <keyword>Multi-targeted Tyrosine Kinase Inhibitor</keyword>
  <keyword>Malignant disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

